NEW YORK () -- Teva Pharmaceutical Industries ( - ) shares are falling 4.11% to $51.65 on Friday morning despite finalizing as much as $2 billion in asset sale agreements, looking to get approval from the Federal Trade Commission (FTC) for its Allergan (AGN) deal.
In July, the Israeli pharmaceutical company agreed to buy Allergan's generic drugs business for $40.5 billion in cash and stock, solidifying Teva's position as the world's' largest generic manufacturer, Reuters reported.
While the deal is expected to close next month, Teva in March said a regulatory review of the deal by the FTC was taking longer than it had projected.
Back by Popular Demand…“Confessions of a...
More